Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease

Gastroenterology

Volumn 118, Issue 4, 2000, Pages 705-713

  Dubinsky, Marla C ^a   Lamothe, Stéphanie ^b   Yang, Hui Ying ^c   Targan, Stephan R ^c   Sinnett, Daniel ^b   Théorêt, Yves ^b   Seidman, Ernest G ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 METHYLTHIOINOSINE; MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; DRUG METABOLISM; ENTERITIS; ERYTHROCYTE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PHARMACOGENOMICS; PRIORITY JOURNAL; SEX DIFFERENCE;

EID: 0034067784     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1016/S0016-5085(00)70140-5     Document Type: Article

References (54)

1. JMT Willoughby, PJ Kumar, J Beckett, and AM. Dawson Controlled trial of azathioprine in Crohn's disease Lancet 731 1971 944 947
2. S Candy, J Wright, M Gerber, G Adams, M Gerig, and R. Goodman A controlled double blind study of azathioprine in the management of Crohn's disease Gut 37 1995 674 678
3. DH Present, BI Korelitz, N Wisch, JL Glass, DB Sachar, and BS. Pasternack Treatment of Crohn's disease with 6-mercaptopurine: a long-term, randomized, double blind study N Engl J Med 302 1980 981 987
4. DC Pearson, GR May, GH Fick, and LR. Sutherland Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis Ann Intern Med 123 1995 132 142
5. JL Rosenberg, AJ Wall, B Levin, HJ Binder, and JB. Kirsner A controlled trial of azathioprine in the management of ulcerative colitis Gastroenterology 69 1975 96 99
6. AB Hawthorne, RF Logan, CJ Hawkey, PN Foster, AT Axon, ET Swarbrick, BB Scott, and JE. Lennard-Jones Randomized controlled trial of azathioprine withdrawal in ulcerative colitis Br Med J 305 1992 20 22
7. J Markowitz, J Rosa, K Grancher, H Aiges, and F. Daum Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease Gastroenterology 99 1990 1347 1351
8. J Markowitz, K Grancher, F Mandel, F Daum, and the 6-MP Collaborative group 6-Mercaptopurine (6-MP) and prednisone therapy for newly diagnosed pediatric Crohn's disease (CD): a prospective multicenter, placebo-controlled clinical trial (abstr) Gastroenterology 114 1998 A4227
9. DH Present, SJ Meltzer, MP Krumholz, A Wolke, and BI. Korelitz 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity Ann Intern Med 111 1989 641 649
10. WR Connell, MA Kamm, JK Ritchie, and JE. Lennard Jones Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience Gut 34 1993 1081 1085
11. ES Goldstein, JF Marion, S Wheeler, and DH. Present Toxicities and infections associated with chronic 6-mercaptopurine (6-MP) use in Crohn's disease (CD): do we need to discontinue treatment? Gastroenterology 114 1998 A4042
12. BS. Kirschner Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease Gastroenterology 115 1998 813 821
13. J Markowitz, K Grancher, F Mandel, and F. Daum Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on immunosuppressive use of the Pediatric IBD Collaborative Research Forum Am J Gastroenterol 88 1993 44 48
14. L. Lennard The clinical pharmacology of 6-mercaptopurine Eur J Clin Pharmacol 43 1992 329 339
15. S Zimm, JM Collins, R Riccardi, D O'Neill, PK Narang, B Chabner, and DG. Poplack Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med 308 1983 1005 1009
16. EC Van Os, BJ Zins, WJ Sandborn, DC Mays, WJ Tremaine, DW Mahoney, AR Zinsmeister, and JJ. Lipsky Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration Gut 39 1996 63 68
17. P Lafolie, S Hayder, O Bjork, and C. Peterson Intraindividual variation in 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute lymphoblastic leukemia Eur J Clin Pharmacol 40 1991 599 601
18. L. Lennard Clinical implications of thiopurine methyltransferase-optimization of drug dosage and potential drug interactions Ther Drug Monitoring 20 1998 527 531
19. GB. Elion The comparative metabolism of imuran and 6-mercaptopurine in man Proc Am Assoc Cancer Res 10 1969 21
20. RM Weinshilboum, and SL. Sladek Mercaptopurine Pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity Am J Hum Genet 32 1980 651 662
21. L Lennard, CA Rees, JS Lilleyman, and JL. Maddocks Childhood leukemia: a relationship between intracellular 6-MP metabolites and neutropenia Br J Clin Pharmacol 16 1983 358 363
22. L Lennard, and JS. Lilleyman Variable 6-mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia J Clin Oncol 7 1989 1816 1823
23. L Lennard, JA Van Loon, and RM. Weinshilboum Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism Clin Pharmacol Ther 46 1989 149 154
24. L Lennard, JS Lilleyman, J Van Loon, and RM. Weinshilboum Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukemia Lancet 336 1990 225 229
25. L Lennard, and JS. Lilleyman Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukemia Lancet 343 1994 1188 1190
26. C Cuffari, Y Théorêt, S Latour, and EG. Seidman 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity Gut 39 1996 401 406
27. C Cuffari, EG Seidman, S Latour, and Y. Théorêt Quantitation of 6-thioguanine in peripheral leukocyte DNA in Crohn's disease patients on maintenance 6-mercaptopurine therapy Can J Physiol Pharmacol 74 1996 580 585
28. JE. Lennard-Jones Classification of inflammatory bowel disease Scand J Gastroenterol 24 suppl 170 1989 2 6 16-19
29. J Myren, IAD Bouchier, G Watkinson, A Softley, SE Clamp, and FT. deDombal The O.M.G.E. multinational inflammatory bowel disease survey 1976-1982. A further report on 2,657 cases Scand J Gastroenterol 95 suppl 1984 1 27
30. SC Truelove, and LJ. Witts Cortisone in ulcerative colitis. Final report on a therapeutic trial Br Med J 2 1955 1041 1044
31. BI Korelitz, and DH. Present Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease Dig Dis Sci 30 1985 58 64
32. LE. Hughes Clinical classification of perianal Crohn's disease Dis Colon Rectum 35 1992 928 932
33. C Szumlanski, D Otterness, C Her, D Lee, B Brandriff, D Kelsell, N Spurr, L Lennard, E Wieben, and R. Weinshilboum Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism DNA Cell Biol 15 1996 17 30
34. H-L Tai, EY Krynetski, CR Yates, T Loennechen, MY Fessing, NF Krynetskaia, and WE. Evans Thiopurine S-methyltransferase deficiency. Two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians Am J Hum Genet 58 1996 694 702
35. E Zietkiewicz, V Yotova, M Jarnik, M Korab-Laskowska, KK Kidd, D Modiano, R Scozzari, M Stoneking, S Tishkoff, M Batzer, and D. Labuda Nuclear DNA diversity in worldwide distributed human populations Gene 205 1997 161 171
36. WJ. Sandborn A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine and methotrexate Am J Gastroenterol 91 1996 423 433
37. CL Szumlanski, and RM. Weinshilboum Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine Br J Clin Pharmacol 39 1995 456 459
38. WE Evans, M Horner, YQ Chu, D Kalwinsky, and WM. Roberts Altered mercaptopurine metabolism, toxic effects and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphoblastic leukemia J Pediatr 119 1991 985 989
39. HL McLeod, DR Miller, and WE. Evans Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient Lancet 341 1993 1151
40. L Lennard, BES Gibson, T Nicole, and JS. Lilleyman Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukemia Arch Dis Child 69 1993 577 579
41. CR Yates, EY Krynetski, T Loennechen, MY Fessing, HL Tai, CH Pui, MV Relling, and WE. Evans Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance Ann Intern Med 126 1997 608 614
42. AJ Black, HL McLeod, HA Capell, RH Powrie, LK Matowe, SC Pritchard, ES Collie-Duguid, and DM. Reid Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine Ann Intern Med 129 1998 716 718
43. LC Woodson, MM Ames, CD Selassie, C Hansch, and RM. Weinshilboum Thiopurine methyltransferase: aromatic thiol substrates and inhibition by benzoic acid derivatives Mol Pharmacol 24 1994 471 478
44. LD Lewis, A Benin, CL Szumlanski, DM Otterness, L Lennard, RM Weinshilboum, and DW. Nierenberg Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction Clin Pharmacol Ther 62 1997 464 475
45. CL Szumlanski, MC Scott, and RM. Weinshilboum Thiopurine methyltransferase pharmacogenetics: human liver enzyme activity Clin Pharmacol Ther 43 1988 134
46. L Lennard, HA Davies, and JS. Lilleyman Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukemia? Br J Cancer 68 1993 186 190
47. LL Bennet, and PW. Allan Formation and significance of 6-methylthiopurine ribonucleotide as a metabolite of 6-mercaptopurine Cancer Res 31 1971 152
48. N Erb, DO Harms, and G. Janka-Schaub Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine Cancer Chemother Pharmacol 42 1998 266 272
49. T Collona, and BI. Korelitz The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease Am J Gastroenterol 89 1994 362 366
50. S Bergan, HE Rugstad, O Bentdal, G Sodal, A Hartmann, T Leivestad, and O. Stokke Monitored high dose azathioprine treatment reduces acute rejection episodes after renal transplantation Transplantation 66 1998 334 339
51. E Schütz, J Gummert, FW Mohr, VW Armstrong, and M. Oellerich Should 6-thioguanine nucleotides be monitored in heart transplant recipients given azathioprine? Ther Drug Monitoring 18 1996 228 233
52. J Markowitz, K Grancher, F Mandel, F Daum, and the 6-MP Collaborative Group Relationship of leukopenia to 6-MP induced remission of Crohn's disease J Pediatr Gastroenterol Nutr 27 1998 A8
53. JF Colombel, I Touze, P Catala, N Ferrari, C Libersa, P Marteau, JP Gendre, B Bonaz, JC Soule, R Modigliani, and F. Broly Genotypic analysis of the thiopurine S-methyltransferase (TPMT) gene in patients with Crohn's disease and severe myelosuppression during azathioprine therapy (abstr) Gastroenterology 116 1999 A688
54. L Lennard, HA Davies, and JS. Lilleyman Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia? Br J Cancer 68 1993 186 190